Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Swords et al
A 2026 BMJ review estimated full weight regain within about 1.7 years
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
The explosive demand for GLP-1 (glucagon-like peptide-1) receptor agonists, driven by their efficacy in treating obesity, has outpaced supply and created a dynamic market landscape
While the supplies have improved, some brand-name medications or doses may still be difficult to find at certain pharmacies
Eloralintide: Efficacy at 12 Weeks, source: Notably, Eli Lilly has initiated a Phase 2 trial evaluating Eloralintide in combination with tirzepatide, aiming to explore a multi-targeted approach to weight management
US$ 22.28
US$ 27.85
US$ 24.88
US$ 28.79
US$ 24.22
US$ 25.08
